155
Participants
Start Date
May 31, 2017
Primary Completion Date
February 22, 2021
Study Completion Date
February 29, 2024
Osimertinib
"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
Bevacizumab
Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
St. James Hospital, Dublin
Mid Western Cancer Centre, Limerick
VU University Medical Centre, Amsterdam
National University Hospital, Singapore
Tan Tock Seng Hospital, Singapore
National Cancer Centre, Goyang
Severance Hospital, Yonsei University Health System, Seoul
Hospital Teresa Herrara, A Coruña
Hospital General Alicante, Alicante
Hospital Sant Pau, Barcelona
ICO Badalona, Barcelona
ICO Hospitalet, Barcelona
OSI Bilbao Basurto, Bilbao
Fund. Jimenez Diaz, Madrid
Hospital de la Princesa, Madrid
Hospital la Paz, Madrid
Hospital Puerta de Hierro, Madrid
Hospital Virgen del Rocio, Seville
Hospital Arnau de Vilanova, Valencia
Hospital General de Valencia, Valencia
Geneva University Hospital (HUG), Geneva
Centre Hospitalier Universitaire Vaudois, Lausanne
Kantonsspital St. Gallen, Sankt Gallen
Kantonsspital Winterthur, Winterthur
UniversitatSpital Zurich, Zurich
Collaborators (1)
AstraZeneca
INDUSTRY
Hoffmann-La Roche
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK